SELENINOTRIGLICERYDY NADZIEJĄ W ZWALCZANIU NOWOTWORÓW

Anna Flis-Borsuk; Lidia Śliwka; Zofia Suchocka; Jakub Borsuk; Zbigniew Fijałek; Katarzyna Lubelska; Piotr Suchocki

doi:10.56782/pps.105

Published : 2016-05-25

Vol. 14 No. 3 (2016)

SELENITETRIGLYCERIDES AND THEIR PROMISE IN CANCER TREATMENT

Anna Flis-Borsuk

Lidia Śliwka

Zofia Suchocka

Jakub Borsuk

Zbigniew Fijałek

Katarzyna Lubelska

Piotr Suchocki

DOI: https://doi.org/10.56782/pps.105

Abstract

Selol is a mixture of selenitetriglycerides, which are unique selenium compounds at the +4 oxidation state. In vitro and in vivo studies have shed light on mechanisms essential for the understanding of the biomedical actions of Selol in health and disease. Following administration, Selol has an initial strong pro-oxidative and antineoplastic effect, while in the second phase it exhibits antioxidant and repair properties. Selol is a promising pharmacological agent with antioxidant, anti-inflammatory, neuroprotective and anti-mutagenic properties. Preclinical studies of Selol are currently nearing completion. Non-commercial clinical pilot studies are in progress, and are based on the biological activity profile of Selol. This review summarizes the current knowledge of the biochemical and molecular properties of Selol and outlines future directions in this area of research.

Most read articles by the same author(s)

Zofia Suchocka, OBESITY - REASONS AND TREATMENT , Prospects in Pharmaceutical Sciences: Vol. 1 No. 1 (2003)
Sylwia Kraczkowska, Zofia Suchocka, Jan Pachecka, ELEVATED BLOOD LEVEL OF HOMOCYSTEINE AS INDICATOR OF HEALTH HAZARD , Prospects in Pharmaceutical Sciences: Vol. 3 No. 3 (2005)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Flis-Borsuk, A., Śliwka, L., Suchocka, Z., Borsuk, J., Fijałek, Z., Lubelska, K., & Suchocki, P. (2016). SELENITETRIGLYCERIDES AND THEIR PROMISE IN CANCER TREATMENT. Prospects in Pharmaceutical Sciences, 14(3), 17–24. https://doi.org/10.56782/pps.105

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Fairweather-Tait S. J., Bao Y., Broadley M. R., Collings R., Ford D., Hesketh J. E., Hurst R. Selenium in human health and disease. Antioxid Redox Signal, 2011, 14(7), 1337-1383. DOI: https://doi.org/10.1089/ars.2010.3275

Rayman M. P. Selenium and human health. Lancet, 2012, 379(9822), 1256-1268. DOI: https://doi.org/10.1016/S0140-6736(11)61452-9

Brown K. M., Arthur J. R. Selenium, selenoproteins and human health: a review. Public Health Nutr, 2001, 4(2b), 593-599. DOI: https://doi.org/10.1079/PHN2001143

Madison T.C. Sanitary report – Fort Randall. In Statistical Report on the Sickness and Mortality in the Army of the United States (Coolidge, R.H., ed.). 36th Congress Senate Exchange Document, 1860, 37-41.

Schwarz K., Foltz C. M. Factor 3 activity of selenium compounds. J. Biol. Chem., 1958, 233, 245–251. DOI: https://doi.org/10.1016/S0021-9258(19)68065-8

Combs G. F., Gray W. P. Food system-based approaches to improving micronutrient nutrition: the case for selenium. Biofactors, 2000, 12(1-4), 39-43. DOI: https://doi.org/10.1002/biof.5520120107

Lu J., Holmgren A. Selenoproteins. J Biol Chem, 2009, 284(2), 723-727. DOI: https://doi.org/10.1074/jbc.R800045200

Clark L. C., Dalkin B., Krongrad A., Combs G. F., Jr., Turnbull B. W., Slate E. H., Witherington R., Herlong J. H., Janosko E., Carpenter D., Borosso C., Falk S., Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol, 1998, 81(5), 730-734. DOI: https://doi.org/10.1046/j.1464-410x.1998.00630.x

Blankenberg S., Rupprecht H. J., Bickel C., Torzewski M., Hafner G., Tiret L., Smieja M., Cambien F., Meyer J., Lackner K. J. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med, 2003, 349(17), 1605-1613. DOI: https://doi.org/10.1056/NEJMoa030535

Rederstorff M., Krol A., Lescure A. Understanding the importance of selenium and selenoproteins in muscle function. Cell Mol Life Sci, 2006, 63(1), 52-59. DOI: https://doi.org/10.1007/s00018-005-5313-y

Hatfield D. L., Berry M. J., Gladyshev V. N. Selenium: Its Molecular Biology and Role in Human Health. Springer Science+Business Media, 2012. DOI: https://doi.org/10.1007/978-1-4614-1025-6

Baum M. K., Campa A. Role of selenium in HIV/AIDS. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium – its molecular biology and role in human health. New York: Springer, 2006, 299-310. DOI: https://doi.org/10.1007/0-387-33827-6_26

Broome C. S., McArdle F., Kyle J. A., Andrews F., Lowe N. M., Hart C. A., Arthur J. R., Jackson M. J. An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. Am J Clin Nutr, 2004, 80(1), 154-162. DOI: https://doi.org/10.1093/ajcn/80.1.154

Rayman M. P., Infante H. G., Sargent M. Food-chain selenium and human health: spotlight on speciation. Br J Nutr, 2008, 100(2), 238-253. DOI: https://doi.org/10.1017/S0007114508922522

Fitak B. A., Grabowski M., Suchocki P. Preparat przeciwnowotworowy i sposób jego wytwarzania. Pol Patent, 1999, 1765301994.

Suchocki P., Jakoniuk D., Fitak B.A. Specific spectrophotometric method with trifluoroacetic acid for the determination of selenium(IV) in selenitetriglycerides. J Pharm Biomed Anal, 2003, 32, 1029-1036. DOI: https://doi.org/10.1016/S0731-7085(03)00205-X

Jastrzebski Z., Czyzewska-Szafran H., Remiszewska M., Fijalek Z., Fitak B. A., Suchocki P. Pharmacokinetics of selol, a new agent containing selenium, in rats. Drugs Exp Clin Res, 1997, 23(1), 7-11.

Jastrzebski Z., Czyzewska-Szafran H., Fijatek Z., Suchocki P., Fitak B. A. Toxicity studies of a new selenium compound, Selol, in rats. Drugs Exp Clin Res, 1995, 21(6), 217-220.

Rahden-Staron I., Suchocki P., Czeczot H. Evaluation of mutagenic activity of the organo-selenium compound Selol by use of the Salmonella typhimurium mutagenicity assay. Mutat Res, 2010, 699(1-2), 44-46. DOI: https://doi.org/10.1016/j.mrgentox.2010.04.018

Schafer F. Q., Buettner G. R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med, 2001, 30(11), 1191-1212. DOI: https://doi.org/10.1016/S0891-5849(01)00480-4

Hutter D. E., Till B. G., Greene J. J. Redox state changes in density-dependent regulation of proliferation. Exp Cell Res, 1997, 232(2), 435-438. DOI: https://doi.org/10.1006/excr.1997.3527

Stipanuk M. H., Ueki I., Dominy J. E., Jr., Simmons C. R., Hirschberger L. L. Cysteine dioxygenase: a robust system for regulation of cellular cysteine levels. Amino Acids, 2009, 37(1), 55-63. DOI: https://doi.org/10.1007/s00726-008-0202-y

Brait M., Ling S., Nagpal J. K., Chang X., Park H. L., Lee J., Okamura J., Yamashita K., Sidransky D., Kim M. S. Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. PLoS One, 2012, 7(9), e44951. DOI: https://doi.org/10.1371/journal.pone.0044951

Sies H. Strategies of antioxidant defense Eur. J. Biochem. , 1993, 215, 213-219. DOI: https://doi.org/10.1111/j.1432-1033.1993.tb18025.x

Carocho M., Ferreira I. C. A review on antioxidants, prooxidants and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem Toxicol, 2013, 51, 15-25. DOI: https://doi.org/10.1016/j.fct.2012.09.021

Lushchak V. I. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids, 2012, 2012, 736837. DOI: https://doi.org/10.1155/2012/736837

Stańczyk M., Jaworska M., Wilk M., Suchocki P., Anuszewska E. The effect of selenium on redox state and thiols changes in lung tissue after Selol, a new organoselenium (IV) compound, administration. Central European Journal of Immunology, 2010, 35(3), 115-122.

Suchocki P., Misiewicz I., Skupinska K., Waclawek K., Fijalek Z., Kasprzycka-Guttman T. The activity of Selol in multidrug-resistant and sensitive human leukemia cells. Oncol Rep, 2007, 18(4), 893-899. DOI: https://doi.org/10.3892/or.18.4.893

Suchocki P., Misiewicz-Krzeminska I., Skupinska K., Niedzwiecka K., Lubelska K., Fijalek Z., Kasprzycka-Guttman T. Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. Pharmacol Rep, 2010, 62(2), 352-361. DOI: https://doi.org/10.1016/S1734-1140(10)70275-9

Curtis D., Klaassen John B., Watkins III, redakcja wydania I polskiego: Barbara Zielińska-Psuja, Andrzej Sapota. Podstawy toksykologii. Casarett & Doull 2014 ISBN: 978-83-7846-058-9, 149-165.

Dudkiewicz-Wilczyńska J., Książek I., Nowak K., Suchocki P., Flis S., Kiljan M., Anuszewska M. Study of the effect of Selol and sodium selenite on HeLa cells in vitro. Chemik, 2011, 65(2), 105-114.

Ksiazek I., Sitarz K., Anuszewska E., Dudkiewicz-Wilczyńska J., Roslon M., Koronkiewicz M., Suchocki P. TOXICITY STUDIES OF SELOL – AN ORGANIC SELENIUM (IV) COMPOUND- IN VITRO RESEARCH International Journal of Pharmacy and Pharmaceutical Sciences 2014, 6(5), 264-269.

Ślusarczyk J., Dudek M., Wierzbicka M., Suchocki P., Kuraś M. Antimitotic effect of Selol and sodium selenate (IV) on Allium test cells. Caryologia, 2014, 67(3), 250-259. DOI: https://doi.org/10.1080/0144235X.2014.974353

Wojciechowska U., Didkowska J. Poprawa przeżyć chorych na nowotwory złośliwe w Polsce. Analiza przeżyć pacjentów zdiagnozowanych w latach 2003–2005. Nowotwory. Journal of Oncology, 2013, 63(4), 279-285. DOI: https://doi.org/10.5603/NJO.2013.0014

El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res, 2001, 475(1-2), 123-139. DOI: https://doi.org/10.1016/S0027-5107(01)00075-6

Ksiazek I., Sitarz K., Roslon M., Anuszewska E., Suchocki P., Wilczynska J. D. The influence of Selol on the expression of oxidative stress genes in normal and malignant prostate cells. Cancer Genomics Proteomics, 2013, 10(5), 225-232.

Flis A., Suchocki P., Królikowska M., Suchocka Z., Remiszewska M., Śliwka L., Książek I., Sitarz K., Sochacka M., Hoser G., Anuszewska E., Wroczyński P., Jastrzębski Z. Selenitetriglycerides—Redox-active agents. Pharmacological Reports, 2015, 67(1), 1-8. DOI: https://doi.org/10.1016/j.pharep.2014.07.017

Nguyen T., Sherratt P. J., Nioi P., Yang C. S., Pickett C. B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem, 2005, 280(37), 32485-32492. DOI: https://doi.org/10.1074/jbc.M503074200

Driscoll D. M.,Copeland P. R. Mechanism and regulation of selenoprotein synthesis. Annu Rev Nutr, 2003, 23, 17-40. DOI: https://doi.org/10.1146/annurev.nutr.23.011702.073318

Hatfield D. L., Gladyshev V. N. How selenium has altered our understanding of the genetic code. Mol Cell Biol, 2002, 22(11), 3565-3576. DOI: https://doi.org/10.1128/MCB.22.11.3565-3576.2002

Lee B. J., Worland P. J., Davis J. N., Stadtman T. C., Hatfield D. L. Identification of a selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense codon, UGA. J Biol Chem, 1989, 264(17), 9724-9727. DOI: https://doi.org/10.1016/S0021-9258(18)81714-8

Miniard A. C., Middleton L. M., Budiman M. E., Gerber C. A., Driscoll D. M. Nucleolin binds to a subset of selenoprotein mRNAs and regulates their expression. Nucleic Acids Res, 2010, 38(14), 4807-4820. DOI: https://doi.org/10.1093/nar/gkq247

Sochacka M., Giebultowicz J., Remiszewska M., Suchocki P., Wroczynski P. Effects of Selol 5% supplementation on the activity or concentration of antioxidants and malondialdehyde level in the blood of healthy mice. Pharmacol Rep, 2014, 66(2), 301-310. DOI: https://doi.org/10.1016/j.pharep.2013.10.004

Zagrodzki P., Bik D., Fitak B.A., Suchocki P., Niemczuk K. Selenoenzymes in animal tissues after supplementation with SELOL. Bulletin of the Veterinary Institute in Puławy, 2000, 44(2).

Barnham K. J., Masters C. L., Bush A. I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov, 2004, 3(3), 205-214. DOI: https://doi.org/10.1038/nrd1330

Martin H. L.,Teismann P. Glutathione--a review on its role and significance in Parkinson's disease. Faseb j, 2009, 23(10), 3263-3272. DOI: https://doi.org/10.1096/fj.08-125443

Wang A. Z., Langer R., Farokhzad O. C. Nanoparticle delivery of cancer drugs. Annu Rev Med, 2012, 63, 185-198. DOI: https://doi.org/10.1146/annurev-med-040210-162544

Poste G., Kirsh R. Site-Specific (Targeted) Drug Delivery in Cancer Therapy. Nat Biotech, 1983, 1(10), 869-878. DOI: https://doi.org/10.1038/nbt1283-869

Falqueiro A. M., Primo F. L., Morais P. C., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C. Selol-loaded magnetic nanocapsules: A new approach for hyperthermia cancer therapy. Journal of Applied Physics, 2011, 109(7), 07B306. DOI: https://doi.org/10.1063/1.3556950

Falqueiro A. M., Siqueira-Moura M. P., Jardim D. R., Primo F. L., Morais P. C., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C. In vitro cytotoxicity of Selol-loaded magnetic nanocapsules against neoplastic cell lines under AC magnetic field activation. Journal of Applied Physics, 2012, 111(7), 07B335. DOI: https://doi.org/10.1063/1.3680541

Estevanato L. L., Da Silva J. R., Falqueiro A. M., Mosiniewicz-Szablewska E., Suchocki P., Tedesco A. C., Morais P. C., Lacava Z. G. Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy. Int J Nanomedicine, 2012, 7, 5287-5299. DOI: https://doi.org/10.2147/IJN.S35279

de Souza L. R., Muehlmann L. A., Dos Santos M. S., Ganassin R., Simon-Vazquez R., Joanitti G. A., Mosiniewicz-Szablewska E., Suchocki P., Morais P. C., Gonzalez-Fernandez A., Azevedo R. B., Bao S. N. PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells. J Nanobiotechnology, 2014, 12, 32. DOI: https://doi.org/10.1186/s12951-014-0032-x